Key Summary
- The National Institute for Health and Care Excellence approves pirtobrutinib for relapsed CLL.
- At-home tablet reduces hospital visits, suits older/unfit patients.
- Works when Bruton’s tyrosine kinase inhibitor treatments fail.
The National Institute for Health and Care Excellence (NICE) has recommended Eli Lilly-manufactured tablet Jaypirca (pirtobrutinib) for patients suffering from recurring chronic lymphocytic leukaemia (CLL).
It will benefit adults facing relapsed CLL and the at-home medication helps them avoid frequent hospital visits.
CLL is a common type of leukaemia in England that develops slowly and turns into a lifelong condition that exhausts the patients physically and emotionally with treatments and relapses.
The drug offers a fresh hope for older adults with other health issues such as kidney diseases as they cannot withstand powerful treatments.
Pirtobrutinib, on the other hand, helps the patients fight the cancer where other treatments like Bruton’s tyrosine kinase (BTK) inhibitor, etc. have failed.
“We heard how important it is for people to have effective treatments available when their disease relapses,” commented Helen Knight, director of medicines evaluation at NICE.
“Our aim is always to make sure that people can access treatments that offer real benefits, while representing a good use of NHS resources,” she added.
